HUTCHMED (NASDAQ:HCM) Rating Increased to Buy at Daiwa Securities Group

HUTCHMED (NASDAQ:HCM) was upgraded by Daiwa Securities Group from a “hold” rating to a “buy” rating in a report released on Thursday, Briefing.com reports.

A number of other brokerages have also commented on HCM. The Goldman Sachs Group cut their target price on HUTCHMED from $16.00 to $14.00 and set a “neutral” rating for the company in a research note on Thursday, July 23rd. Weiss Ratings downgraded shares of HUTCHMED from a “hold (c-)” rating to a “sell (d)” rating in a research note on Friday, July 31st. Bank of America reduced their target price on shares of HUTCHMED from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. Wall Street Zen upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, Morgan Stanley set a $13.60 price objective on HUTCHMED in a report on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $14.87.

HUTCHMED Price Performance

NASDAQ HCM traded up $2.15 during trading hours on Thursday, hitting $14.19. The company had a trading volume of 330,293 shares, compared to its average volume of 47,015. HUTCHMED has a 1-year low of $9.77 and a 1-year high of $18.30. The business has a 50 day moving average of $11.61 and a 200-day moving average of $12.73. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.50 and a current ratio of 5.64.

HUTCHMED (NASDAQ:HCM) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.14 by ($0.09). The business had revenue of $139.14 million during the quarter, compared to the consensus estimate of $304.16 million. Analysts forecast that HUTCHMED will post 0.23 earnings per share for the current fiscal year.

Institutional Investors Weigh In On HUTCHMED

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC raised its stake in shares of HUTCHMED by 128.0% during the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock worth $3,343,000 after acquiring an additional 124,771 shares in the last quarter. UBS Group AG boosted its holdings in HUTCHMED by 112.8% in the 3rd quarter. UBS Group AG now owns 137,000 shares of the company’s stock valued at $2,158,000 after purchasing an additional 72,614 shares during the last quarter. Amundi raised its stake in shares of HUTCHMED by 41.9% in the 3rd quarter. Amundi now owns 223,330 shares of the company’s stock valued at $3,620,000 after acquiring an additional 65,898 shares during the period. XY Capital Ltd increased its stake in HUTCHMED by 115.2% during the 2nd quarter. XY Capital Ltd now owns 104,130 shares of the company’s stock worth $1,120,000 after buying an additional 55,736 shares during the period. Finally, M&G PLC grew its position in shares of HUTCHMED by 26.7% during the fourth quarter. M&G PLC now owns 259,033 shares of the company’s stock worth $3,367,000 after buying an additional 54,601 shares in the last quarter. Hedge funds and other institutional investors own 8.82% of the company’s stock.

More HUTCHMED News

Here are the key news stories impacting HUTCHMED this week:

• Positive Sentiment: GSK will receive exclusive rights to develop and commercialize HMPL-A830 outside Mainland China, Hong Kong, Macau and Taiwan. HUTCHMED is eligible for up to $1.295 billion, including a reported $110 million upfront payment, development and regulatory milestones, and commercial payments. HUTCHMED signs licensing deal with GSK for experimental solid tumour drug
• Positive Sentiment: HMPL-A830 is described as a potentially first-in-class KRAS-EGFR antibody-targeted therapy conjugate for solid tumors and is expected to enter clinical trials in the second half of 2026. The partnership gives the program GSK’s global development and commercialization resources while preserving HUTCHMED’s rights in Greater China. HUTCHMED Announces Licensing Agreement with GSK
• Positive Sentiment: Analysts at Cavendish and Panmure Liberum reiterated their “buy” ratings, arguing that the GSK transaction highlights a valuation disconnect and that investors may be underestimating HUTCHMED’s broader oncology pipeline. Panmure and Cavendish reiterate buy on Hutchmed after GSK deal
• Positive Sentiment: A separate late-stage study involving HUTCHMED’s Orpathys and AstraZeneca’s Tagrisso in lung cancer also reported a successful outcome, adding another potential catalyst for the company’s oncology portfolio. AstraZeneca, Hutchmed succeed in late-stage lung cancer trial
• Neutral Sentiment: The HMPL-A830 payments are milestone-dependent, and the therapy has not yet entered clinical trials. Future valuation gains therefore depend on clinical efficacy, regulatory progress and eventual commercialization. HUTCHMED discusses strategic partnership with GSK

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.